C4 Therapeutics, Inc. - Director's Dealing 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: C4 Therapeutics, Inc. (CCCC)
CIK: 0001662579
Period of Report: 2021-12-08

Reporting Person: Fisher Stewart (Chief Scientific Officer)

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-12-08	Common Stock	M	2373	$2.11	Acquired	25117	Direct
2021-12-08	Common Stock	M	17786	$3.71	Acquired	42903	Direct
2021-12-08	Common Stock	M	403	$4.98	Acquired	43306	Direct

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-12-08	Stock Option (Right to Buy)	$2.11	M	2373	Disposed	2026-07-12	Common Stock (2373)	Direct
2021-12-08	Stock Option (Right to Buy)	$3.71	M	17786	Disposed	2028-04-23	Common Stock (17786)	Direct
2021-12-08	Stock Option (Right to Buy)	$4.98	M	403	Disposed	2030-07-02	Common Stock (403)	Direct

F1: This option is fully vested and exercisable as of the date hereof.

F2: 20% of this option vested and became exercisable on May 1, 2019, with the remainder vesting in 16 equal quarterly installments thereafter.

F3: This option shall vest and become exercisable in 20 equal quarterly installments, with the first installment vesting on September 5, 2020.